FDA Greenlights Guardant Health's Shield Blood Test, Analyst Cautious on Adoption

On Monday, the FDA approved Guardant Health Inc.'s GH Shield blood test for colorectal cancer (CRC) screening in adults age 45 and older who are at average risk for the disease. The company says it is the first blood test approved by the FDA as a primary screening option for CRC, meaning healthcare providers can offer Shield like all other non-invasive methods recommended in screening guidelines. Colorectal cancer is the second-leading cause of cancer-related death in the U.S., even though it is highly trea ...